Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07115654) titled 'BCMA/CD3 BsAb Therapy for POEMS Syndrome' on Aug. 4.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Condition: POEMS Syndrome

Intervention: Drug: CM336 (BCMA/CD3 bispecific antibody)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 10, 2025

Target Sample Size: 10

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07115654

Published by HT Digital...